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S646 VALUE IN HEALTH - NOVEMBER 2019Objectives: The study assesses the global annual cost of people living with HIV
(PLWHIV) in France in 2013 and affiliated to the general insurance scheme during
2008-2015. Methods: We performed a retrospective cohort study in the SNIIRAM
database containing individualized data on all reimbursed health expenses for the
French population. PLWHIV were identified by specific chronic diseases status
and/or reimbursement of HIV laboratory tests and/or HIV-related hospitalizations
and/or reimbursements of antiretroviral drugs in 2013. Each patient was followed
two years after his inclusion. Hospital and outpatient costs were estimated and
categorized in 13 subgroups: antiretroviral drugs, daily sick leave benefits, other
drugs, paramedical visits, general practitioner visits, specialist visits, medical
devices, transports, laboratory tests, other outpatient costs, hospital stays, hospital
outpatient consultations and hospital at home. Costing was performed considering
French official tariffs for 2013 and 2014 and expressed in 2019 euros. Results: A
cohort of 96,423 PLWHIV was identified. Mean age was 47.5 years old (612), 65%
were men, and most frequent treatments outside HIV drugs were treatments for
cardiovascular disease (20%), psychotropic treatments (16%) and liver disease
(15%). The total annual cost of PLWHIV was calculated to V1.4 billion, split into
antiretroviral drugs for 63% (870MV), hospital stays for 11% (154MV), daily sick
leave benefits for 8% (116MV), other drugs for 5% (73MV). The median annual cost
per patient was estimated to be V12,094 [610,801, Q1: 9,001, Q3: 16,795],
varying from V618 for 0-10 years old PLWHIV to V13,725 for 51-60 years old
PLWHIV, V11,969 for incident patients (N=3,373), and V13,560 for patients with at
least one comorbidity. Conclusions: This study shows that the global annual cost
of PLWHIV is mainly charged to antiretroviral drugs cost. Only thin disparities in
total cost were observed in each group (age, incident, comorbidity), advanced analyses
such as Machine Learning could identify significantly overexpressing cost profiles.
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Objectives: V114, an investigational 15-valent pneumococcal conjugate vaccine
(PCV) is under development that contains all serotypes in PCV10 and PCV13 and 2
additional serotypes (22F/33F). This study quantifies the health and economic
burden of invasive pneumococcal disease (IPD) associated with V114 serotypes in
Finland, the Netherlands and Austria. Methods: A Markov model was developed to
simulate V114-type IPD cases, deaths and costs in hypothetical unvaccinated birth
cohorts over 20 years. All inputs were obtained from the published literature. In the
pre-PCV analysis, epidemiological inputs from the pre-PCV7 era were applied to all
serotypes. In the post-PCV analysis, pre-PCV7 and pre-PCV10 inputs were applied to
PCV7 serotypes and PCV10 not PCV7 (PCV10-PCV7) serotypes. Disease attributable to
V114 not PCV10 (V114-PCV10) serotypes were estimated using the most recent data.
Costs were estimated from a societal perspective (2017 Euros) and discounted at 3%.
Results: In the pre-PCV analysis, 355 V114-type IPD cases would occur: 244 (69%)
attributable to PCV7 serotypes, 53 (15%) to PCV10-PCV7 serotypes, and 58 (16%) to
V114-PCV10 serotypes. V114 serotypes caused 74 IPD deaths. Costs of V114-type IPD
wasV9.4 million. In the post-PCV analysis, V114-type IPD increased to 406 cases: 244
(60%) attributable to PCV7 serotypes, 66 (16%) to PCV10-PCV7 serotypes, and 96
cases (24%) to V114-PCV10 serotypes. Compared to the pre-PCV analysis, the addi-
tional 13 cases attributable to PCV10-PCV7 serotypes were mainly caused by sero-
type 1. The additional 38 cases attributable to V114-PCV10 serotypes were from
serotypes 3 (33 cases, 91%) and 19A (11 cases, 31%). Costs of V114-type IPD increased
to V10.4 million. Deterministic sensitivity analysis will be performed. Con-
clusions: PCV7 serotypes cause most IPD-related morbidity and costs and should be
retained in investigational PCVs. Serotypes contained in PCV10 and PCV13 also
contribute to IPD morbidity and cost. Expanding coverage to non-vaccine serotypes
can prevent additional disease.
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Objectives: Stigmas associated with HIV in the Kingdom of Saudi Arabia (KSA) have
resulted in decreased testing in those at high risk of acquiring HIV infection; ulti-
mately, this increases the clinical, humanistic, and economic burden on KSA. To
assess the cost incurred due to the impact of these stigmas, we hypothesized that
addressing the consequences of these stigmas on diagnosis rates, through testing of
pregnant women to prevent mother-to-child transmission (PMTCT) and HIV self-
testing (HIVST), will lead to an increase in the number of diagnosed and linked-to-care patients. The resulting cost savings would be indicative of the cost associated
with stigma. Hence, a health-economic model was developed to estimate the cost-
effectiveness of these interventions in KSA. Methods: A Markov model was built to
estimate the costs associated with people living with HIV (PLHIV) subject to pre-
vention of mother-to-child transmission (PMTCT) and HIVST, over 20-years (control).
Data sources included the KSA National AIDS Programme, Demographic Survey 2016
(KSA General Authority for Statistics) and UNAIDS. The model included seven health
states: general population, undiagnosed, diagnosed, treated, and symptomatic HIV
patients, deaths due to HIV, and background mortality. Stigmas related to having
unprotected sex, testing for HIV infection as a member of a risk group, and seeking
treatment if infected, were included. Base-case scenario was maintaining status quo
and not implementing either interventions. Results: Over the 20-year horizon,
implementing PMTCT and HIVST prevented 12,800 and 15,600 new infections
respectively vs. the base-case. Additionally, Implementing PMTCT and HIVST are
projected to have a net cost saving of 151.4 and 336.9 million SAR respectively from
the country’s estimated expenditures on HIV management over 20 years. Con-
clusions: PMTCT and HIVST are cost-saving stigma-addressing interventions for
PLHIV in KSA. Not addressing stigma in high-risk groups and general population
could result in incurring a sizable “cost of stigma”.
PIN39
WHEN A PROBIOTIC-BASED SANITIZING METHOD MAY
HALVE HEALTHCARE-ASSOCIATED INFECTIONS AND
REDUCE ASSOCIATED COSTS
Rognoni C,1 Arnoldo L,2 Brusaferro S,2 Caselli E,3 Mazzacane S,4
Tarricone R5
1Centre for Research on Health and Social Care Management (CERGAS), SDA
Bocconi School of Management, Bocconi University, Milan, MI, Italy,
2Department of Medicine, University of Udine, Udine, Italy, Udine, Italy,
3Section of Microbiology and Medical genetics, Department of Medical
Sciences, University of Ferrara, Ferrara, Italy, CIAS Research Interdepartmental
Centre, Departments of Architecture and Medical Sciences, University of
Ferrara, Ferrara, Italy, Italy, Ferrara, Italy, 4CIAS Research Interdepartmental
Centre, Departments of Architecture and Medical Sciences, University of
Ferrara, Ferrara, Italy, Ferrara, Italy, 5SDA Bocconi School of Management,
Milan, Italy
Objectives: Healthcare-associated infections (HAIs) are among the major causes of
morbidity and mortality in healthcare settings. In Italy, the incidence of HAIs is 5-10%
and infections caused by antibiotic-resistant microorganisms report a mortality rate
of 20-30%. Healthcare environments play an important role in the transmission of
HAIs and conventional chemicals-based sanitation shows limitations in controlling
surface contamination and related HAIs onset. Recently, a sanitizing procedure based
on probiotic detergents (Probiotic Cleaning Hygiene System - PCHS) showed to
decrease surface pathogens up to 90% more than conventional disinfectants. This
study aimed at evaluating the economic impact of the management of HAIs with
PCHS versus chemicals-based sanitation in Italy. Methods: A multicentre, prospec-
tive, pre-post interventional protocol has been implemented in 5 Italian Hospitals to
perform a cost-minimization analysis by comparing the management of HAIs related
to pre-intervention (conventional disinfectants) and post-intervention (PCHS) pha-
ses, from the hospital perspective. The healthcare resource consumption focused on
antibiotic therapy considering that the two sanitizing systems have comparable
costs. A propensity-score matching has been performed in order to select, for both
periods, patients with overlapping clinical characteristics. Results: Data were
collected from 01.01.2016 to 30.06.2016 for conventional disinfectants and from
01.01.2017 to 30.06.2017 for PCHS, for a total of 11,461 patients. The total number of
patients in the two periods after matching resulted 8,320 (4,160 per group). During
the pre-phase 191 patients developed at least one HAI and 100 patients developed at
least one HAI during the post-phase, showing an incidence rate ratio of 0.47 (CI 95%
0.37-0.60). The total cost for antibiotic therapy resulted 52,004V and 10,954V for
conventional disinfectants and PCHS, respectively, highlighting a cost reduction of
78.9%. Conclusions: Our analysis revealed that PCHS may be a cost-saving strategy
compared to conventional disinfectants considering the cost of the management of
HAIs related to antibiotic therapy.
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Objectives: According to the recently approved rules in Russia, new treatment could
enter the reimbursement list only if ICER for it is lower than for the previously
included drugs for the same clinical situation. Our objective was to assess cost
effectiveness of direct-acting antivirals (DAA) in comparison with historically used
combination of pegylated interferon with ribavirin (PR) for HCV genotype 1 in
treatment-naïve and treatment-experienced patients to set the willingness-to-pay
threshold for this condition. Methods: We estimated lifetime costs and outcomes in
previously developed model for the treatment-naïve and treatment-experienced
patients with HCV genotype1 with and without cirrhosis. The rates of sustained
